Frederick Mohr
Plus aucun poste en cours
Historique de carrière de Frederick Mohr
Anciens postes connus de Frederick Mohr
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ZS PHARMA INC | Directeur/Membre du Conseil | 17/12/2015 | - |
Bristol-Myers Squibb Holdings Ltd.
 Bristol-Myers Squibb Holdings Ltd. MiscellaneousMiscellaneous Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Holdings Ltd. is a holding British company. The company is based in Uxbridge, UK. | Corporate Officer/Principal | - | - |
| ASTRAZENECA PLC | Compliance Officer | - | - |
| SIO GENE THERAPIES INC. | Conseiller Juridique Général | 06/06/2017 | - |
Formation de Frederick Mohr
| Yale University | Undergraduate Degree |
| University of Virginia School of Law | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Royaume-Uni | 3 |
Opérationnelle
| General Counsel | 1 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
| Miscellaneous | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Bristol-Myers Squibb Holdings Ltd.
Bristol-Myers Squibb Holdings Ltd. MiscellaneousMiscellaneous Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Holdings Ltd. is a holding British company. The company is based in Uxbridge, UK. | Miscellaneous |
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
- Bourse
- Insiders
- Frederick Mohr
- Expérience
